3. Oakley P, Kisely S, Baxter A, et al. Increased mortality among people with schizophrenia and other non-affective psychotic disorders in the community: a systematic review and meta-analysis. J Psychiatr Res 2018;102:245-253.
5. Oh J, Nam H, Park S, Chae JH, Kim TS. Decreased cardiovascular death in schizophrenia patients treated with antipsychotics: a Korean national cohort study. Schizophr Res 2021;228:417-424.
7. Chang J, Kim JA, Kim K, et al. Association of antipsychotics adherence and cardiovascular disease among newly diagnosed schizophrenia patients: a national cohort among Koreans. Asian J Psychiatr 2020;52:102161.
9. Kugathasan P, Johansen MB, Jensen MB, Aagaard J, Nielsen RE, Jensen SE. Coronary artery calcification and mortality risk in patients with severe mental illness. Circ Cardiovasc Imaging 2019;12:e008236.
13. Lee NY, Roh MS, Kim SH, et al. The prevalence of metabolic syndrome and its association with alanine aminotransferase in clozapine-treated Korean patients with schizophrenia. Int Clin Psychopharmacol 2013;28:71-79.
15. Kelly DL, McMahon RP, Wehring HJ, et al. Cigarette smoking and mortality risk in people with schizophrenia. Schizophr Bull 2011;37:832-838.
17. Vancampfort D, Knapen J, Probst M, Scheewe T, Remans S, De Hert M. A systematic review of correlates of physical activity in patients with schizophrenia. Acta Psychiatr Scand 2012;125:352-362.
20. Wadhera RK, Bhatt DL, Kind AJ, et al. Association of outpatient practice-level socioeconomic disadvantage with quality of care and outcomes among older adults with coronary artery disease: implications for value-based payment. Circ Cardiovasc Qual Outcomes 2020;13:e005977.
22. Dipasquale S, Pariante CM, Dazzan P, Aguglia E, McGuire P, Mondelli V. The dietary pattern of patients with schizophrenia: a systematic review. J Psychiatr Res 2013;47:197-207.
23. Ryu S, Nam HJ, Oh S, et al. Eating-behavior changes associated with antipsychotic medications in patients with schizophrenia as measured by the drug-related eating behavior questionnaire. J Clin Psychopharmacol 2013;33:120-122.
24. Jauhar S, Johnstone M, McKenna PJ. Schizophrenia. Lancet 2022;399:473-486.
25. Taipale H, Mittendorfer-Rutz E, Alexanderson K, et al. Antipsychotics and mortality in a nationwide cohort of 29,823 patients with schizophrenia. Schizophr Res 2018;197:274-280.
28. Solmi M, Fiedorowicz J, Poddighe L, et al. Disparities in screening and treatment of cardiovascular diseases in patients with mental disorders across the world: systematic review and meta-analysis of 47 observational studies. Am J Psychiatry 2021;178:793-803.
31. Montaquila JM, Trachik BJ, Bedwell JS. Heart rate variability and vagal tone in schizophrenia: a review. J Psychiatr Res 2015;69:57-66.
35. Rødevand L, Rahman Z, Hindley GF, et al. Characterizing the shared genetic underpinnings of schizophrenia and cardiovascular disease risk factors. Am J Psychiatry 2023;180:815-826.
36. Pillinger T, Osimo EF, de Marvao A, et al. Effect of polygenic risk for schizophrenia on cardiac structure and function: a UK Biobank observational study. Lancet Psychiatry 2023;10:98-107.
40. Townsend L, Pillinger T, Selvaggi P, Veronese M, Turkheimer F, Howes O. Brain glucose metabolism in schizophrenia: a systematic review and meta-analysis of 18FDG-PET studies in schizophrenia. Psychol Med 2023;53:4880-4897.
41. De Prisco M, Oliva V, Fico G, et al. Emotion dysregulation in bipolar disorder compared to other mental illnesses: a systematic review and meta-analysis. Psychol Med 2023:1-20.
42. Yun JY, Lee JS, Kang SH, et al. Korean treatment guideline on pharmacotherapy of co-existing symptoms and antipsychotics-related side effects in patients with schizophrenia. Korean J Schizophr Res 2019;22:21-33.
44. Hasson-Ohayon I, Arnon-Ribenfeld N, Hamm JA, Lysaker PH. Agency before action: the application of behavioral activation in psychotherapy with persons with psychosis. Psychotherapy (Chic) 2017;54:245-251.
46. Korman N, Stanton R, Vecchio A, et al. The effect of exercise on global, social, daily living and occupational functioning in people living with schizophrenia: a systematic review and meta-analysis. Schizophr Res 2023;256:98-111.
49. Jeon DW, Shim JC, Kong BG, et al. Adjunctive varenicline treatment for smoking reduction in patients with schizophrenia: a randomized double-blind placebo-controlled trial. Schizophr Res 2016;176:206-211.
50. O’Reilly CL, Bell JS, Kelly PJ, Chen TF. Exploring the relationship between mental health stigma, knowledge and provision of pharmacy services for consumers with schizophrenia. Res Social Adm Pharm 2015;11:e101-e109.